{"organizations": [], "uuid": "89ad067618c67b3fa658824402e6cf8d43baf2ee", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/novo-nordisk-drug/novo-nordisk-says-haemophilia-drug-data-support-clinical-profile-idUSL5N1SS33M", "country": "US", "domain_rank": 408, "title": "Novo Nordisk says haemophilia drug data support clinical profile", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.714, "site_type": "news", "published": "2018-05-21T21:08:00.000+03:00", "replies_count": 0, "uuid": "89ad067618c67b3fa658824402e6cf8d43baf2ee"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/novo-nordisk-drug/novo-nordisk-says-haemophilia-drug-data-support-clinical-profile-idUSL5N1SS33M", "ord_in_thread": 0, "title": "Novo Nordisk says haemophilia drug data support clinical profile", "locations": [], "entities": {"persons": [{"name": "mads krogsgaard thomsen", "sentiment": "none"}], "locations": [{"name": "copenhagen", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novo nord", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - A head-to-head trial showed that people with haemophilia B who received Novo Nordisk’s Refixia achieved greater total factor IX exposure than those treated with recombinant factor IX-Fc Fusion Protein, the Danish company said on Monday.\n* People with haemophilia B have congenital factor IX deficiency and are either missing or have a malfunctioning factor IX protein, which is needed for proper blood clotting\n* “These head-to-head data support the strong clinical profile of Refixia,” chief science officer Mads Krogsgaard Thomsen said in a press release. (Reporting by Copenhagen newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-21T21:08:00.000+03:00", "crawled": "2018-05-22T19:19:46.000+03:00", "highlightTitle": ""}